BR112014032264A2 - composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo - Google Patents
composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativoInfo
- Publication number
- BR112014032264A2 BR112014032264A2 BR112014032264A BR112014032264A BR112014032264A2 BR 112014032264 A2 BR112014032264 A2 BR 112014032264A2 BR 112014032264 A BR112014032264 A BR 112014032264A BR 112014032264 A BR112014032264 A BR 112014032264A BR 112014032264 A2 BR112014032264 A2 BR 112014032264A2
- Authority
- BR
- Brazil
- Prior art keywords
- prevention
- treatment
- composition
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120065193A KR101386697B1 (ko) | 2012-06-18 | 2012-06-18 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| PCT/KR2013/005068 WO2013191401A1 (ko) | 2012-06-18 | 2013-06-10 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 질환의 치료 또는 예방용 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014032264A2 true BR112014032264A2 (pt) | 2017-06-27 |
| BR112014032264A8 BR112014032264A8 (pt) | 2022-03-03 |
Family
ID=49768959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014032264A BR112014032264A8 (pt) | 2012-06-18 | 2013-06-10 | Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9511068B2 (pt) |
| EP (1) | EP2862573B1 (pt) |
| JP (1) | JP6030234B2 (pt) |
| KR (1) | KR101386697B1 (pt) |
| CN (2) | CN104582704A (pt) |
| BR (1) | BR112014032264A8 (pt) |
| CA (1) | CA2876926C (pt) |
| ES (1) | ES2668908T3 (pt) |
| MX (1) | MX365021B (pt) |
| RU (2) | RU2014151382A (pt) |
| WO (1) | WO2013191401A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101498973B1 (ko) | 2013-11-21 | 2015-03-05 | 현대모비스(주) | 차량용 주차 지원 시스템 및 방법 |
| GB201401005D0 (en) * | 2014-01-21 | 2014-03-05 | Ucl Business Plc | Inhibitor |
| KR101778004B1 (ko) * | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| GB0201882D0 (en) | 2002-01-28 | 2002-03-13 | Novartis Ag | Organic compounds |
| WO2003086178A2 (en) | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| ES2297490T3 (es) * | 2003-07-23 | 2008-05-01 | Bayer Pharmaceuticals Corporation | Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones. |
| NZ546088A (en) | 2003-08-27 | 2009-10-30 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders using a PDGF antagonist and a VEGF antagonist |
| GB0421438D0 (en) * | 2004-09-27 | 2004-10-27 | Astrazeneca Ab | Combination therapy |
| AU2005249159A1 (en) * | 2004-06-04 | 2005-12-15 | Bioniche Life Sciences Inc. | Use of imatinib to treat liver disorders and viral infections |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| WO2006035203A1 (en) | 2004-09-27 | 2006-04-06 | Astrazeneca Ab | Cancer combination therapy comprising azd2171 and imatinib |
| EP1802308A1 (en) * | 2004-10-08 | 2007-07-04 | Novartis AG | Combination of organic compounds |
| PT1893213E (pt) | 2005-06-03 | 2010-04-19 | Novartis Ag | Combinação de compostos pirimidilaminobenzamida e imatinib para tratamento ou prevenção de doenças proliferativas |
| US20080003219A1 (en) * | 2005-09-26 | 2008-01-03 | Minu, L.L.C. | Delivery of an ocular agent |
| EP1920767A1 (en) | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| JP2010509289A (ja) | 2006-11-09 | 2010-03-25 | アボット ゲーエムベーハー ウント コンパニー カーゲー | チロシンキナーゼ阻害剤の経口投与用薬学的剤形 |
| EP2305263B1 (en) | 2007-06-07 | 2012-09-19 | Novartis AG | Stabilized amorphous forms of imatinib mesylate |
| TW201102068A (en) * | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
| KR101138840B1 (ko) | 2009-12-28 | 2012-05-10 | 주식회사 셀트리온화학연구소 | 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물 |
-
2012
- 2012-06-18 KR KR1020120065193A patent/KR101386697B1/ko active IP Right Grant
-
2013
- 2013-06-10 CN CN201380032289.9A patent/CN104582704A/zh active Pending
- 2013-06-10 EP EP13807815.9A patent/EP2862573B1/en active Active
- 2013-06-10 RU RU2014151382A patent/RU2014151382A/ru unknown
- 2013-06-10 MX MX2014015785A patent/MX365021B/es active IP Right Grant
- 2013-06-10 JP JP2015518325A patent/JP6030234B2/ja active Active
- 2013-06-10 CA CA2876926A patent/CA2876926C/en active Active
- 2013-06-10 RU RU2018128737A patent/RU2018128737A/ru unknown
- 2013-06-10 ES ES13807815.9T patent/ES2668908T3/es active Active
- 2013-06-10 CN CN201710777309.5A patent/CN107496426A/zh active Pending
- 2013-06-10 WO PCT/KR2013/005068 patent/WO2013191401A1/ko active Application Filing
- 2013-06-10 BR BR112014032264A patent/BR112014032264A8/pt not_active Application Discontinuation
- 2013-06-10 US US14/409,441 patent/US9511068B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018128737A (ru) | 2019-03-14 |
| JP2015520226A (ja) | 2015-07-16 |
| BR112014032264A8 (pt) | 2022-03-03 |
| EP2862573A1 (en) | 2015-04-22 |
| EP2862573A4 (en) | 2016-01-27 |
| ES2668908T3 (es) | 2018-05-23 |
| KR20130141998A (ko) | 2013-12-27 |
| RU2014151382A (ru) | 2016-08-10 |
| US20150320750A1 (en) | 2015-11-12 |
| MX2014015785A (es) | 2015-06-10 |
| WO2013191401A1 (ko) | 2013-12-27 |
| RU2018128737A3 (pt) | 2019-03-14 |
| US9511068B2 (en) | 2016-12-06 |
| CN104582704A (zh) | 2015-04-29 |
| CA2876926A1 (en) | 2013-12-27 |
| CA2876926C (en) | 2017-04-04 |
| MX365021B (es) | 2019-05-20 |
| CN107496426A (zh) | 2017-12-22 |
| KR101386697B1 (ko) | 2014-04-18 |
| JP6030234B2 (ja) | 2016-11-24 |
| EP2862573B1 (en) | 2018-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015003376A8 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| WO2013012915A9 (en) | Heterocyclic compounds and uses thereof | |
| CO7061081A2 (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| BR112014028395A2 (pt) | derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer | |
| EP2671586A4 (en) | PHARMACOTHERAPY FOR THE PREVENTION OR TREATMENT OF GLAUCOMA | |
| EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
| LTPA2020511I1 (lt) | Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui | |
| GT201400161A (es) | Fenilimidazopirazoles sustituidos y su uso | |
| CL2014003123A1 (es) | 5-amino [1,4], tiazinas como inhibidores de bace1; uso del compuesto contra la enfermedad de alzheimer. | |
| EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
| EP2990040A4 (en) | Therapeutic agent for eyeground disease | |
| PL3031465T3 (pl) | Kompozycja farmaceutyczna do sprzyjania tworzeniu tkanki kostnej, zawierająca jako składnik czynny wyciąg z liści stauntonia hexaphylla | |
| HK1207579A1 (en) | Composition for preventing or treating heart disease | |
| EP3311817A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE | |
| EP2799082A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORAL DISEASES OR ASTHMA CONTAINING A STOREM STEREMIA OVALIFOLIA EXTRACT OR A FRACTION OF IT AS AN ACTIVE SUBSTANCE | |
| BR112014032264A2 (pt) | composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo | |
| EP2910246A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH ENOBLOCK AS AN ACTIVE SUBSTANCE | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| EP2873419A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AZATHIOPRIN AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF BRAIN TUMORS OR TUMODAL RESISTANT GLIOBLASTOMES | |
| EP2870971A4 (en) | MEDICAMENT FOR THE PREVENTION / TREATMENT OF AN OCULAR DISEASE | |
| PT2938328T (pt) | Fármaco monolítico para a libertação modificada de uma combinação de princípios ativos | |
| EP2789337A4 (en) | PHARMACEUTICAL COMPOSITION WITH BICYCLIC PYRIDINOL DERIVATIVES FOR PREVENTING OR TREATING ANTICIPATED ANALYSIS OF ANGIOGENESIS | |
| PL2704698T3 (pl) | Postać leku do kontrolowanego uwalniania substancji czynnych |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |